Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Astonea Labs IPO
Price Band
₹128.0–135.0
Issue Size
₹37.67 Cr
Lot Size
1,000 shares
Min Investment
₹135,000
GMP
—
Issue Price
₹135.0
Astonea Labs IPO AI Summary
- Astonea Labs IPO is listed on BSE SME in the Pharmaceuticals sector.
- Price band: ₹128.0–₹135.0 per share, lot size 1,000 shares (min. investment ₹135,000).
- Subscription window: 27 May–29 May 2025, listing on 03 Jun 2025.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Astonea Labs IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 29 May 2025 — not a current signal.
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Astonea Labs IPO Grey Market Premium (GMP) Today
GMP not available yet
Grey Market Premium is updated daily. Check back closer to the listing date.
About the Company
Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies both within India and internationally. The company manufactures and markets a variety of pharmaceutical and cosmetic products, including antibiotics, anti-cold medicines, antihistamines, and treatments for diabetes, heart, gynecological issues, infections, and more. The company offers skin, tooth, and hair care products in forms like gels, creams, and serums, and also trades packaging and raw materials for pharmaceutical and cosmetic industries, meeting industry standards. The company engages in contract manufacturing of pharmaceutical and cosmetic products, markets its own brands "Glow Up" and "Regero," plans to launch "Avicel," and exports to countries like Iraq and Yemen. Produts and Offerings: Products under our own brands: The company markets “Glow Up” skincare and “Regero” pharma products, offering diverse affordable solutions. Products under contract manufacturing: The company provides pharmaceutical and cosmetic products under contract manufacturing, primarily for domestic and export markets. As of August 16, 2024, the company had 217 employees on payroll. Competitive Strengths: Experienced management and dedicated employee base Scalable business model Wide and diverse range of product offerings Quality Service
Company Financials (₹ Cr)
As of 2024-12-31
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 96.52 | 80.89 | 64.28 | 52.91 |
| Total Income | 69.69 | 80.29 | 67.26 | 30.17 |
| Profit After Tax | 4.10 | 3.81 | 0.67 | 0.25 |
| NET Worth | 17.28 | 11.97 | 8.16 | 7.49 |
| Reserves and Surplus | 9.56 | 4.37 | 4.16 | 3.49 |
| Total Borrowing | 49.48 | 42.40 | 35.99 | 29.52 |
Key Ratios
EPS
₹4.93
NAV
₹15.75
ROE
37.86%
ROCE
22.95%
RoNW
31.83%
P/B Value
8.57
P/E Ratio
27.36
Market Cap
₹141.90 Cr
PAT Margin
4.75%
Debt/Equity
2.16
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Beta Drugs Limited | 163.43 | 23.19% | 49 | 37.9 | 37.9 |
| Astonea Labs Ltd This IPO | 15.75 | 31.83% | — | 5.01 | 5.01 |
Promoters
Ashish Gulati
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Funding of expenses proposed to be incurred towards registration in Bolivia, South America 1.29 2 Purchase and installation of plant and machineries for ointment production for the purpose of export in accordance with the international standards and protocols, on the 2nd floor of the Existing Premises 5.23 3 Advertising, marketing and brand building 4.95 4 Investment in procuring hardware and software 0.68 5 Funding of Working Capital Requirements 19.75 6 General Corporate Purposes 1.99 7 Issue Expenses 3.77 Total 37.67
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total Income was ₹30.17 Cr in the period ending 31 Mar 2022, rising to ₹67.26 Cr by 31 Mar 2023, and further increasing to ₹80.29 Cr by 31 Mar 2024. However, it decreased to ₹69.69 Cr in the most recent period ending 31 Dec 2024, though this is a 9-month figure, not a full year, so isn't directly comparable.
Profit Trend
Profit After Tax was ₹0.25 Cr in the period ending 31 Mar 2022, increasing to ₹0.67 Cr by 31 Mar 2023, and then rising to ₹3.81 Cr by 31 Mar 2024. It further increased to ₹4.10 Cr in the most recent period ending 31 Dec 2024, though this is a 9-month figure, not a full year, so isn't directly comparable.
Valuation
At the issue price of ₹135.0, Astonea Labs Ltd has an implied P/E ratio of 27.36, compared to peers like Beta Drugs Limited, which trades at a P/E of 49.
Grey Market Premium, Explained
The Grey Market Premium (GMP) is an indicator of the demand for an IPO before it officially lists on the stock exchange. A high GMP suggests strong investor interest, while a low or negative GMP indicates weaker demand. However, GMP is not a guaranteed predictor of listing day performance.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their risk tolerance, investment goals, and market conditions. It's important to consider the company's growth potential and market position.
Who May Want to Wait
Investors who are risk-averse or have a low tolerance for market fluctuations may want to avoid investing in IPOs like this, as they can experience significant price volatility in the early days of trading.
IPO Timeline, Explained
The IPO has an open date of May 27, 2025, and will close on May 29, 2025. Allotment of shares is expected on May 30, 2025, with the listing date set for June 3, 2025.
Listing Gains — The Risk
Listing day gains can be unpredictable and depend on various factors, including market conditions and investor sentiment. While some IPOs may see a significant rise on their first day, others may not perform as well. Investors should be prepared for the possibility of both gains and losses.
This evaluation is generated from Astonea Labs's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is the price band of Astonea Labs IPO?
The price band of Astonea Labs IPO is ₹128.0–₹135.0 per share.
When does Astonea Labs IPO open and close?
Astonea Labs IPO opens on 27 May 2025 and closes on 29 May 2025.
When does Astonea Labs IPO list on the stock exchange?
Astonea Labs IPO listed on 03 June 2025 at ₹135.0.
What is the lot size for Astonea Labs IPO?
The lot size for Astonea Labs IPO is 1000 shares, requiring a minimum investment of ₹135,000.
What is the lot size for Astonea Labs IPO?
The lot size for Astonea Labs IPO is 1000 shares.
What is the minimum investment required?
The minimum investment required is ₹135,000.
What is the price band for the IPO?
The price band for the IPO is ₹128.0 to ₹135.0.
When does the IPO open and close?
The IPO opens on May 27, 2025, and closes on May 29, 2025.
When will the shares be listed?
The shares are expected to be listed on June 3, 2025.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
27 May 2025
Close
29 May 2025
Allotment
30 May 2025
Listing
03 Jun 2025
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Astonea Labs?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.